EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY-NC 4.0

Glucagon-Like Peptide-1 Receptor Agonists: What’s the Optimizing Policies for Obesity-Related Metabolic Diseases?

Tae Sun Park

Diabetes & Metabolism Journal · 01.03.2025 · 49 (2) · 169-171

DOI: 10.4093/dmj.2025.0047 ↗

Kurz gefasst

Editorial in der Zeitschrift Diabetes & Metabolism Journal, erschienen am 01.03.2025. Verfasst von Tae Sun Park. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Jeonbuk National University Medical School, Research Institute of Clinical…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute…

Zitieren

APA

Park, T. S. (2025). Glucagon-Like Peptide-1 Receptor Agonists: What’s the Optimizing Policies for Obesity-Related Metabolic Diseases?. Diabetes & Metabolism Journal, 49(2), 169-171. https://doi.org/10.4093/dmj.2025.0047

Vancouver

Park TS. Glucagon-Like Peptide-1 Receptor Agonists: What’s the Optimizing Policies for Obesity-Related Metabolic Diseases?. Diabetes & Metabolism Journal. 2025;49(2):169-171. doi:10.4093/dmj.2025.0047

BibTeX
@article{Park2025,
  author = {Park, Tae Sun},
  title = {Glucagon-Like Peptide-1 Receptor Agonists: What’s the Optimizing Policies for Obesity-Related Metabolic Diseases?},
  journal = {Diabetes & Metabolism Journal},
  year = {2025},
  volume = {49},
  number = {2},
  pages = {169--171},
  doi = {10.4093/dmj.2025.0047}
}
Kostenlos starten →